Mankind Pharma announced its financial results for the third quarter (Q3 FY25), reflecting strong growth across key financial and operational metrics.
Financial Highlights:
- Net Profit: ₹380.2 crores (16.2% YoY decline)
- Revenue: ₹3,230 crores (24% YoY increase)
- EBITDA: ₹830 crores (36.8% YoY growth)
- EBITDA Margin: 25.7% vs 23.3% (previous year)
The company demonstrated impressive top-line growth, with revenue expanding by 24% compared to the same quarter last year. Despite a slight dip in net profit, Mankind Pharma improved its EBITDA and margin performance, indicating operational efficiency and strong market positioning.
Mankind Pharma’s stock closed today at ₹2,620, marking a significant daily gain. The stock touched a high of ₹2,670 and low of ₹2,497, reflecting strong market interest. With a 52-week range of ₹1,901.05 to ₹3,054.80, the stock shows significant growth potential.
TOPICS:
Mankind Pharma